Search

Your search keyword '"Palm, D."' showing total 971 results
Start Over Author "Palm, D."

Refine your results

more »

more »

more »

more »

more »
971 results on '"Palm, D."'

1. Feasibility Assessment of 5G Use Cases in Intralogistics

Author

Dietrich, F., Angos Mediavilla, M., Turgut, A., Lackner, T., Jooste, W., Palm, D., Behrens, Bernd-Arno, Series Editor, Grzesik, Wit, Series Editor, Ihlenfeldt, Steffen, Series Editor, Kara, Sami, Series Editor, Ong, Soh-Khim, Series Editor, Tomiyama, Tetsuo, Series Editor, Williams, David, Series Editor, von Leipzig, Konrad, editor, Sacks, Natasha, editor, and Mc Clelland, Michelle, editor

Published
2023
Full Text
View/download PDF

25. Motor system abnormalities in hereditary spastic paraparesis type 4 (SPG4) depend on the type of mutation in the spastin gene

Author

Bonsch, D, Schwindt, A, Navratil, P, Palm, D, Neumann, C, Klimpe, S, Schickel, J, Hazan, J, Weiller, C, Deufel, T, and Liepert, J

Subjects
Gene mutations -- Physiological aspects -- Research -- Methods -- Analysis -- Health aspects -- Genetic aspects, DNA -- Genetic aspects -- Analysis -- Research -- Health aspects -- Physiological aspects -- Methods, Nervous system diseases -- Genetic aspects -- Health aspects -- Research, Patients -- Health aspects -- Medical examination -- Genetic aspects -- Physiological aspects -- Research -- Methods -- Analysis, Genotype -- Physiological aspects -- Health aspects -- Research -- Analysis -- Genetic aspects -- Methods, Heredity -- Genetic aspects -- Health aspects -- Physiological aspects -- Methods -- Analysis -- Research, Clinical neuropsychology -- Research -- Health aspects -- Analysis -- Physiological aspects -- Methods, Phenotype -- Genetic aspects -- Physiological aspects -- Research -- Health aspects -- Analysis -- Methods, Health, Psychology and mental health, Analysis, Physiological aspects, Medical examination, Genetic aspects, Research, Methods, Health aspects
Abstract

Background: Hereditary spastic paraparesis (HSP) denotes a group of inherited neurological disorders with progressive lower limb spasticity as their clinical hallmark; a large proportion of autosomal dominant HSP belongs to [...]

Published
2003

30. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with non-alcoholic fatty liver

Author

Grimaudo, S., primary, Bartesaghi, S., additional, Rametta, R., additional, Marra, F., additional, Mancina, R.M., additional, Pihlajamäki, J., additional, Kakol-Palm, D., additional, Andréasson, A.C., additional, Dongiovanni, P., additional, Fracanzani, A.L., additional, Lori, G., additional, Männistö, V., additional, Pellegrini, G., additional, Bohlooly-Y, M., additional, Pennisi, G., additional, Pipitone, R.M., additional, Spagnuolo, R., additional, Craxì, A., additional, Lindén, D., additional, Valenti, L., additional, Romeo, S., additional, and Petta, S., additional

Published
2020
Full Text
View/download PDF

33. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials: report of a consensus meeting

Author

Miller, V., Pantaleo, G., Tiemessen, C.T., Kuritzkes, D., Schacker, T., Stephenson, K., Julg, B., Sugarman, J., Colby, D.J., Sogaard, O.S., Dee, L., Ananworanich, J., Nixon, D.F., Michael, N.L., Johnston, R., Dube, K., Palm, D., Goulder, P., Jefferys, R., Tressler, R., Dawson, L., Likhitwonnawut, U., Spudich, S., Tebas, P., Eron, J., Robb, M.L., Frater, J., Weiss, C.D., Sheikh, V., Barouch, D.H., van Lunzen, J., Peay, H., Geleziunas, R., Zheng, L., Deeks, S.G., Bar, K., Hanna, G.J., Martinez-Picado, J., Walker, B.D., Salzwedel, K., Mellors, J.W., Dong, K.L., Li, J.Z., Gandhi, R.T., Salzwedel, J., Taylor, J., Caskey, M., Persaud, D., and Montaner, L.J.

Abstract

Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.

Published
2019
Full Text
View/download PDF

40. Impact of Adult Attention Deficit Hyperactivity Disorder and Medication Status on Sleep/Wake Behavior and Molecular Circadian Rhythms

Author

Coogan, Andrew, Schenk, M, Palm, D, Uzoni, A, Grube, J, Tsang, A H, Kolbe, I, McGowan, N M, Wandschneider, R, Colla, M, Oster, H, Thorne, J, Faltraco, Frank, Coogan, Andrew, Schenk, M, Palm, D, Uzoni, A, Grube, J, Tsang, A H, Kolbe, I, McGowan, N M, Wandschneider, R, Colla, M, Oster, H, Thorne, J, and Faltraco, Frank

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neuropsychiatric condition that has been strongly associated with changes in sleep and circadian rhythms. Circadian rhythms are near 24-h cycles that are primarily generated by an endogenous circadian timekeeping system, encoded at the molecular level by a panel of clock genes. Stimulant and non-stimulant medication used in the management of ADHD has been shown to potentially impact on circadian processes and their behavioral outputs. In the current study, we have analyzed circadian rhythms in daily activity and sleep, and the circadian gene expression in a cohort of healthy controls (N = 22), ADHD participants not using ADHD-medication (N = 17), and participants with ADHD and current use of ADHD medication (N = 17). Rhythms of sleep/wake behavior were assessed via wrist-worn actigraphy, whilst rhythms of circadian gene expression were assessed ex-vivo in primary human-derived dermal fibroblast cultures. Behavioral data indicate that patients with ADHD using ADHD-medication have lower relative amplitudes of diurnal activity rhythms, lower sleep efficiency, more nocturnal activity but not more nocturnal wakenings than both controls and ADHD participants without medication. At the molecular level, there were alterations in the expression of PER2 and CRY1 between ADHD individuals with no medication compared to medicated ADHD patients or controls, whilst CLOCK expression was altered in patients with ADHD and current medication. Analysis of fibroblasts transfected with a BMAL1:luc reporter showed changes in the timing of the peak expression across the three groups. Taken together, these data support the contention that both ADHD and medication status impact on circadian processes.

Published
2019

49. Determinanten der Arzneimittelforschung

Author

Dengler, H. J., primary, Eichelbaum, M., additional, Kroemer, H. K., additional, Palm, D., additional, Wellstein, A., additional, Schloos, J., additional, Belz, G. G., additional, Herrmann, M., additional, Kruse, W., additional, Weber, E., additional, and von Bergmann, K., additional

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results